Unlocking Insights: PROs & Quality of Life After HCT : Oncology Times
An abstract is unavailable.
An abstract is unavailable.
After noticing a lump on the right side of his neck, Chu Nguyen, Ph.D., came to MD Anderson for a second opinion. Further testing revealed…
The field of central nervous system (CNS) oncology is rapidly changing with advances in molecular diagnostics. The therapeutic implications are being realized …
An abstract is unavailable.
The current health care economy has driven many employers to self-funding models to offer affordable health care coverage to employees.
We’re thrilled to announce that the Program in Physical Therapy has been named THE #1 Physical Therapy Program in the Country by US News and…
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible…
Tislelizumab has been approved in Europe across 3 indications in the first and second line for select patients with non–small cell lung cancer.
In the frontline, patient body mass index plays a prognostic role when using atezolizumab plus bevacizumab vs lenvatinib for patients with advanced hepatocellular carcinoma.
About 4% of US cancer survivors surveyed said they adhere to the American Cancer Society’s nutrition and physical activity guidelines.
Health Canada has approved subcutaneous atezolizumab for use in patients with lung cancer, breast cancer, and hepatocellular carcinoma.